Helse Bergen HF Haukeland Universitetssjukehus

MIDDLETON, Wis., Aug. 7, 2024 /PRNewswire/ -- Natus Medical Incorporated has announced the launch of autoSCORE, the first-of-its-kind artificial intelligence model capable of automatic and comprehensive clinical EEG interpretation, providing accuracy on par with medical experts. Continue Reading "The development of the world's first AI model capable of reading clinical EEGs at the level of the best experts in the world is a significant accomplishment," says Harald Aurlien, co-founder of Holberg EEG and a consultant in clinical neurophysiology at Haukeland University Hospital. Post this Natus Neuro CEO Chris Landon introduces autoSCORE, an innovative AI application that can positively affect clinical outcomes in the diagnosis and treatment of epilepsy patients through expert-level clinical EEG interpretation Natus announces autoSCORE, the world's first-of-its-kind AI model capable of automatic and comprehensive clinical EEG interpretation. The autoSCORE application was developed in Norway by Holberg EEG using a deep-learning model and trained on the world's largest dataset of more than 30,000 expertly labeled EEG recordings. The development and validation of the model have been carefully designed to avoid typical errors and sources of bias, and the output is focused on aspects key to the interpretation of clinical EEGs [1]. "The development of the world's first AI model capable of reading clinical EEGs at the level of the best experts in the world is a significant accomplishment," says Harald Aurlien, co-founder of Holberg EEG and a consultant in clinical neurophysiology at Haukeland University Hospital. "The partnership and distribution agreement with Natus, one of the world's largest EEG companies, will help bring this innovative solution to customers around the world." The 2023 study "Automated Interpretation of Clinical Electroencephalograms Using Artificial Intelligence," published in JAMA, revealed autoSCORE consistently performed with accuracy, sensitivity, and specificity near or above 90% [1]. It also showed the autoSCORE application to be on par with leading human experts while outperforming similar AI models on the market. "The autoSCORE application has the potential to improve clinical outcomes and value of care for the millions suffering from epilepsy," states Natus Neuro Chief Executive Officer Chris Landon. "This newly launched solution represents the first of what we expect will be a series of innovative AI applications at Natus designed to deliver efficiency and quality improvements across healthcare." Visual EEG review is considered the gold standard for determining abnormalities, but it demands clinical resources and years of specialized training. The AI-enabled autoSCORE application is designed to allow neurocare teams to more efficiently and consistently perform EEG data analysis. Unlike traditional spike and seizure detectors, the autoSCORE application comprehensively assesses EEG data for multiple clinically relevant abnormalities and provides study-level assessments to inform care teams whether an EEG study is normal or abnormal. The autoSCORE application has received U.S. Food and Drug Administration clearance for use with routine EEG studies and is currently available in the United States, exclusively with Natus NeuroWorks EEG Software Version 10. ABOUT NATUS Natus is trusted by healthcare providers around the globe as the solution source to screen, diagnose, and treat disorders affecting the brain, neural pathways, and sensory nervous systems. The best-in-class Natus solutions, including service, field support and education, enable clinicians to advance their standard of care, improving patient outcomes and quality of life. ABOUT HOLBERG EEG Holberg EEG is a spin-off company from the Haukeland University Hospital in Bergen, Norway. Its mission is to unite structured data to be used for new innovations to improve patient care. The company's current focus is EEG and to gain new knowledge and understanding of the complex brain using artificial intelligence on a huge database of structured labeled EEGs. Tveit, J., et al., Automated Interpretation of Clinical Electroencephalograms Using Artificial Intelligence. JAMA Neurology, 2023. CONTACT: Lisa Schuler Sr. Director, Corporate Communications Phone: +1 612 528-1332 Email: [email protected] SOURCE Natus Medical Incorporated

PORTO, Portugal, Feb. 21, 2024 /PRNewswire/ -- A team of researchers from Germany, the USA, the UK, and Norway won the third edition of the BIAL Award in Biomedicine, a 300,000 Euro prize promoted by the BIAL Foundation, which seeks to recognise a work in biomedicine of exceptional quality and scientific relevance published in the last ten years. Continue Reading Lead researchers of the winning team of the BIAL Award in Biomedicine 2023 promoted by the BIAL Foundation. Photo credits: Thomas Kuner - Hendrik Schröder, Heidelberg University Hospital; Frank Winkler - berlin-event-foto.de; Varun Venkataramani - Carina Kircher and Gerald Bendner. Led by researchers Varun Venkataramani (first author), Frank Winkler, and Thomas Kuner (senior co-authors) from the University of Heidelberg in Germany, the study "Glutamatergic synaptic input to glioma cells drives brain tumour progression", published in Nature in 2019, represents breakthrough research important for understanding human cancer, specifically glioblastomas, a very aggressive type of brain tumour with an average survival time of just 1.5 years, even with state-of-the-art treatment. In this work, the authors showed that glioblastomas and other incurable gliomas can integrate themselves into the function of the brain, and that input from healthy brain cells, normally used in functions such as thinking and memory, drives the progression of gliomas. This is possible by formation of synapses between neurons and cancer cells. For the president of the Jury, "these findings are a major and surprising advance in the understanding of how brain cancer progresses, by describing a new communication channel between neurons and the tumour and by suggesting specific avenues for treatment". This paper shows that cancer cells cannot merely proliferate - they have to hijack healthy biological processes and integrate themselves into the normal function of tissues. "Nowhere is this more blatant - and surprising - than in the brain tumours studied in this paper", says Ralph Adolphs. The award-winning research also provides a new explanation for why epilepsy and tumour progression are often observed together: epilepsy may be a cause, rather than a consequence of the tumour progression. The winning paper, chosen from 70 nominations, is co-authored by 29 researchers from Heidelberg University, Heidelberg University Hospital, German Cancer Research Center, University Hospital Mannheim, Otto-von-Guericke University (Germany), Johns Hopkins University School of Medicine (USA), University of Glasgow (UK), University of Bergen, and Haukeland University Hospital (Norway). It should be noted that two of the scientists who won the 2021 edition of this Award, Katalin Karikó, and Drew Weissman, were awarded the 2023 Nobel Prize in Physiology or Medicine for their discoveries that enabled the development of vaccines based on mRNA to prevent COVID-19. Photo - Logo -

PORTO, Portugal, Feb. 21, 2024 /PRNewswire/ -- A team of researchers from Germany, the USA, the UK, and Norway won the third edition of the BIAL Award in Biomedicine, a 300,000 Euro prize promoted by the BIAL Foundation, which seeks to recognise a work in biomedicine of exceptional quality and scientific relevance published in the last ten years. Continue Reading Lead researchers of the winning team of the BIAL Award in Biomedicine 2023 promoted by the BIAL Foundation. Photo credits: Thomas Kuner - Hendrik Schröder, Heidelberg University Hospital; Frank Winkler - berlin-event-foto.de; Varun Venkataramani - Carina Kircher and Gerald Bendner. Led by researchers Varun Venkataramani (first author), Frank Winkler, and Thomas Kuner (senior co-authors) from the University of Heidelberg in Germany, the study "Glutamatergic synaptic input to glioma cells drives brain tumour progression", published in Nature in 2019, represents breakthrough research important for understanding human cancer, specifically glioblastomas, a very aggressive type of brain tumour with an average survival time of just 1.5 years, even with state-of-the-art treatment. In this work, the authors showed that glioblastomas and other incurable gliomas can integrate themselves into the function of the brain, and that input from healthy brain cells, normally used in functions such as thinking and memory, drives the progression of gliomas. This is possible by formation of synapses between neurons and cancer cells. For the president of the Jury, "these findings are a major and surprising advance in the understanding of how brain cancer progresses, by describing a new communication channel between neurons and the tumour and by suggesting specific avenues for treatment". This paper shows that cancer cells cannot merely proliferate - they have to hijack healthy biological processes and integrate themselves into the normal function of tissues. "Nowhere is this more blatant - and surprising - than in the brain tumours studied in this paper", says Ralph Adolphs. The award-winning research also provides a new explanation for why epilepsy and tumour progression are often observed together: epilepsy may be a cause, rather than a consequence of the tumour progression. The winning paper, chosen from 70 nominations, is co-authored by 29 researchers from Heidelberg University, Heidelberg University Hospital, German Cancer Research Center, University Hospital Mannheim, Otto-von-Guericke University (Germany), Johns Hopkins University School of Medicine (USA), University of Glasgow (UK), University of Bergen, and Haukeland University Hospital (Norway). It should be noted that two of the scientists who won the 2021 edition of this Award, Katalin Karikó, and Drew Weissman, were awarded the 2023 Nobel Prize in Physiology or Medicine for their discoveries that enabled the development of vaccines based on mRNA to prevent COVID-19. Photo - Logo - SOURCE BIAL Foundation